Page 79 - Book Hosokawa Nanoparticle Technology Handbook

2.1 STRUCTURE CONSTRUCTION AND FUNCTION ADAPTATION OF NANOPARTICLES FUNDAMENTALS
Gd-DTPA in the tumor led to significant tumor [12] H. Ichikawa, S. Kaneko and Y. Fukumori, Chem.
growth suppression in Gd-NCT trials in vivo. Pharm. Bull., 44, 383–391 (1996).
[13] H. Ichikawa, Y. Fukumori: J. Controlled Release, 63,
2.1.6 Summary 107–119 (2000).
[14] A. Bjornerud, L.O. Johansson and H.K. Ahlstrom:
The structures of nanoparticles were briefly MAGMA, 12, 99–103 (2001).
explained. Their structures should be as simple as [15] M.F. Kircher, J.R. Allport, E.E. Graves, V. Love,
possible for manufacturing purpose. However, func- L. Josephson, A.H. Lichtman and R. Weissleder:
tional adaptation in specific applications very often Cancer Res., 63, 6838–6346 (2003).
requires some complicated structures, and uses of
very specific molecular interactions. Although the [16] E.A. Schellenberger, A. Bogdanov Jr., D. Hogemann,
nanostructure construction to achieve desired func- J. Tait, R. Weissleder and L. Josephson: Mol. Imaging,
tions is not easy in the present stage of nanotechnol- 1, 102–107 (2002).
ogy, nanoparticles will be beneficial in wide [17] Y. Zhang, N. Kohler and M. Zhang: Biomaterials, 23,
applications due to their behaviors intrinsic in the 1553–1561 (2002).
nano scale. [18] D. Hogemann, L. Josephson, R. Weissleder and
Nanoparticles designed and prepared for wider J.P. Basilion: Bioconjugate Chem., 11, 941–946
applications will be introduced in the following (2000).
section.
[19] H. Onishi, Y. Machida and Y. Machida: Biol. Pharm.
Bull., 26, 116–119 (2003).
[20] J.S. Chawla, M.M. Amiji: Int. J. Pharm., 249,
References
127–138 (2002).
[1] Y. Fukumori, H. Ichikawa: Ad. Powder Technol., 17, [21] K. Kataoka, A. Harada and Y. Nagasaki: Adv. Drug
1–28 (2006). Delivery Rev., 47, 113–131 (2001).
[2] A. Ito, H. Honda and T. Kobayashi: Chem. Eng. Jpn., [22] J.D. Hood, M. Bednarski, R. Frausto, S. Guccione,
67(12), 692–695 (2003). R.A. Reisfeld, R. Xiang and D.A. Cheresh: Science,
[3] K. Maruyama, O. Ishida, T. Takizawa and K. Moribe: 296, 2404–2407 (2002).
Ad. Drug Delivery Rev., 40, 89–102 (1999). [23] N.C. Bellocq, S.H. Pun, G.S. Jensen and M.E. Davis:
[4] L. Li, C.A. Wartchow, S.N. Danthi, Z. Shen, Bioconjugate Chem., 14, 1122–1132 (2003).
N. Dechene, J. Pease, H.S. Choi, T. Doede, P. Chu, [24] M. Kabbaj, N.C. Phillips: J. Drug Target., 9, 317–328
S. Ning, D.Y. Lee, M.D. Bednarski and S.J. Knox: Int. (2001).
J. Radiat. Oncol. Biol. Phys., 58, 1215–1227 (2004). [25] H. Tokumitsu, H. Ichikawa and Y. Fukumori: Pharm.
[5] M. Miyamoto, H. Hirano, H. Ichikawa, Y. Fukumori, Res., 16, 1830–1835 (1999).
Y. Akine, K. Tokuuye: Chem. Pharm. Bull., 47, [26] F. Shikata, H. Tokumitsu, H. Ichikawa and
203–208 (1999). Y. Fukumori: Eur. J. Pharm. Biopharm., 53, 57–63
[6] M. Miyamoto, K. Hirano, H. Ichikawa, Y. Fukumori, (2002).
Y. Akine, K. Tokuuye: Biol. Pharm. Bull., 22, [27] H. Tokumitsu, J. Hiratsuka, Y. Sakurai, T. Kobayashi,
1331–1340 (1999). H. Ichikawa and Y. Fukumori: Cancer Lett., 150,
[7] T. Watanabe, H. Ichikawa, Y. Fukumori: Eur. 177–182 (1999).
J. Pharm. Biopharm., 54, 119–124 (2002). [28] M.O. Oyewumi, R.A. Yokel, M. Jay, T. Coakley and
[8] H. Ichikawa, H. Tokumitsu, M. Miyamoto and R.J. Mumper: J. Control. Release, 95, 613–626
Y. Fukumori: Nanoparticles for neutron capture (2004).
therapy of cancer, in Nanotechnologies for the Life [29] M.O. Oyewumi, S. Liu, J.A. Moscow and R.J.
Sciences, Vol. 6, Wiley-VCH, Berlin, pp. 87–121 Mumper: Bioconjugate Chem., 14, 404–411 (2003).
(2006). [30] M.O. Oyewumi, R.J. Mumper: Int. J. Pharm., 251,
[9] M.E. Akerman, W.C. Chan, P. Laakkonen, S.N. Bhatia 85–97 (2003).
and E. Ruoslahti: Proc. Natl. Acad. Sci. USA, 99, [31] M.O. Oyewumi, R.J. Mumper: Bioconjugate Chem.,
12617–12621 (2002). 13, 1328–1335 (2002).
[10] Y. Fukumori, K. Takada and H. Takeuchi: [32] M.O. Oyewumi, R.J. Mumper: Drug Dev. Ind.
Nanotechnologies for the Life Sciences, Vol. 10, Pharm., 28, 317–328 (2002).
Wiley-VCH, Berlin, pp. 255–308 (2006). [33] Z. Cui and R.J. Mumper: Bioconjugate Chem., 13,
[11] H. Ichikawa, H. Tokumitsu, K. Jono, T. Fukuda, 1319–1327 (2002).
Y. Osako, Y. Fukumori: Chem. Pharm. Bull., 42, [34] P.J. Stevens, M. Sekido and R.J. Lee: Anticancer Res.,
1308–1314 (1994). 24(1), 161–165 (2004).

55